These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include:
Pipeline and key clinical candidates for these companies:
Eiger Biopharma is a commercial-stage biopharmaceutical company focused on the development of innovative therapies to treat Hepatitis Delta Virus, or HDV, and other serious rare diseases.
Harpoon Therapeutics is a clinical-stage immuno-oncology company developing a novel class of T cell engagers that harness the power of the body’s immune system to treat patients suffering from cancer and other diseases using its proprietary Tri-specific T cell Activating Construct, or TriTAC, platform. Harpoon is developing a pipeline of novel TriTACs initially focused on the treatment of solid tumors and hematologic malignancies. Harpoon has also developed a proprietary ProTriTAC platform, which applies a prodrug concept to its TriTAC platform to create a therapeutic T cell engager that remains inactive until it reaches the tumor. Harpoon’s third proprietary technology platform, extended release TriTAC-XR, is designed to mitigate cytokine release syndrome.
Fennec Pharmaceuticals is focused on the development and commercialization of Pedmark to reduce the risk of platinum-induced ototoxicity in pediatric patients. Pedmark received FDA approval in September and has received Orphan Drug Designation in the U.S. Fennec has a license agreement with Oregon Health and Science University for exclusive worldwide license rights to intellectual property directed to sodium thiosulfate and its use for chemoprotection, including the reduction of risk of ototoxicity induced by platinum chemotherapy, in humans.
Alnylam markets commercial RNAi therapeutic products Onpattro, Givlaari, Oxlumo, Amvuttra and Leqvio, which is being developed and commercialized by Alnylam’s partner, Novartis (NVS). Alnylam has a pipeline of investigational medicines, including multiple product candidates that are in late-stage development.
ADMA Biologics is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. ADMA currently manufactures and markets three FDA-approved plasma-derived biologics for the treatment of immune deficiencies and the prevention of certain infectious diseases.
Recent news on these stocks:
Harpoon Therapeutics presented updated interim data from its Phase 1 clinical trial evaluating single-agent HPN217 in relapsed/refractory multiple myeloma in a poster presentation at the 64th American Society of Hematology Annual Meeting and Exposition being held in person and virtually in New Orleans. HPN217 targets B-cell maturation antigen and is based on Harpoon's proprietary Tri-specific T cell Activating Construct platform designed to recruit a patient's own immune cells to kill tumor cells.
Eiger BioPharmaceuticals announced topline primary Week 48 data from its Phase 3 D-LIVR study evaluating lonafarnib, a first-in-class prenylation inhibitor, in two regimens in patients with chronic Hepatitis Delta Virus, or HDV: lonafarnib boosted with ritonavir alone and in combination with peginterferon alfa - combination -. The composite primary endpoint was a greater than or equal to2 log decline in HDV RNA and normalization of alanine aminotransferase at the end of 48 weeks of treatment compared to placebo. Topline Week 48 results showed that both treatment arms achieved statistical significance over placebo in the composite primary endpoint as well as the component virologic and biochemical responses.
Alnylam Pharmaceuticals announced the submission of its supplemental New Drug Application to the FDA for patisiran, an investigational RNAi therapeutic in development for the treatment of transthyretin-mediated amyloidosis with cardiomyopathy. Patisiran is the established name for ONPATTRO, which is currently approved by the U.S. FDA for the treatment of the polyneuropathy of hereditary ATTR amyloidosis in adults.
ADMA Biologics priced its previously announced underwritten public offering of 20.98M shares of its common stock at a public offering price of $2.86 per share, resulting in gross proceeds of approximately $60 million before deducting underwriting discounts and commissions and other estimated offering expenses.
About “Biotech Alert”
The Fly will report on a selection of biotech stocks seeing a surge in interest from retail and financial professional investors, based on data from InvestingChannel.
This Fly exclusive recap reveals the biotech stocks that are seeing a spike in searches among the 15-plus million retail and financial professional investors through InvestingChannel's online financial news media ecosystem.
This increased attention from the investors may be in response to, or advance of, outsized moves for stocks in the biotech sector, which tend to be volatile and prone to sharp swings in share price around binary events such as clinical study results and FDA approvals.